Skip to main content
Figure 3 | Nutrition & Metabolism

Figure 3

From: Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

Figure 3

Mean pre and post-dose serum BHB levels at each study visit. Post-dose samples were taken 2 hours after administration of investigational product. Blue bars represent Placebo, red bars represent AC-1202. Error bars represent standard error of the mean. Significant increases in BHB levels were found post-dose in AC-1202 subjects compared to Placebo subjects. Subjects were given 1/2 dose at Baseline (10 grams), full dose on Days 45 and 90 (20 grams), and no dose was administered on Day 104. Asterisks (*) represent significant differences between AC-1202 and Placebo groups (p < 0.0001).

Back to article page